Where Every Peptide Stands on the FDA 503A Bulks List (17 November 2026)
The short version, as of 17 November 2026
- No peptide in this table has been added to the 503A bulks list. We found no proposed or final rule doing so. FDA's category list was last updated on 14 May 2026.
- The advisory committee backed six of seven peptides in July 2026. BPC-157, KPV, TB-500, MOTS-c, epitalon and semax were recommended, emideltide (DSIP) was not. FDA published no vote counts, so the tallies below come from a law-firm summary.
- A separate HHS policy covers six peptides. On 30 October 2026 HHS published an enforcement discretion policy for those six, tied to named routes. It is interim and not binding, and it does not put anything on the list.
- Still in Category 2 on the 14 May 2026 list: ibutamoren mesylate and kisspeptin-10, both voted down in October 2024.
Pharmacists, lawyers and reporters keep asking the same question: where does a given peptide stand on the FDA's list of bulk substances that pharmacies may compound with? This page answers it one peptide at a time, from FDA, Federal Register and HHS documents only. Every row names its sources, and every source was read on 17 November 2026. It is a record of what the documents say, not legal advice and not medical advice.
How a peptide gets onto the list
- Nomination. Someone asks FDA to add a bulk substance to the 503A list for a stated use.
- Category. Under FDA's interim policy, nominated substances sit in Category 1 (under evaluation), Category 2 (significant safety risks) or Category 3 (nominated without adequate support), or are withdrawn by the nominator.
- Advisory committee. FDA staff write a briefing document and propose a position. The Pharmacy Compounding Advisory Committee (PCAC) votes. A yes vote means the substance should be placed on the list. The vote is advice only.
- Rulemaking. FDA must propose a rule, take comments and finalise it. No such rule exists for any peptide in this table.
- Final list. Only a final rule puts a substance on the 503A bulks list.
Separate layer: on 30 October 2026 HHS published an enforcement discretion policy. It says HHS does not intend to act against certain compounders using six named peptides under set conditions, while rulemaking continues. It sits beside the ladder and does not move a peptide up it. Our reading of the text: HHS published its peptide compounding policy.
The matrix: 26 peptides, one row each
Included: every peptide on FDA's 503A Category 1, 2 or 3 list of 14 May 2026, every peptide that went to the PCAC in 2024 to 2026, every peptide FDA lists as nominated but withdrawn, and the six in the HHS policy. A "yes" in a vote means the member voted to place the substance on the list. Where a cell says "not published", the pages we read do not give the fact and we have not guessed it.
| Peptide | Nominated for (use) | Category 2 added | Removed from Category 2 | 503A category on FDA list updated 14 May 2026 | PCAC meeting, tally and FDA staff recommendation | In HHS 30 Oct 2026 enforcement discretion policy | 503B status where FDA lists one | Next known event | Sources (read 17 Nov 2026) |
|---|---|---|---|---|---|---|---|---|---|
| BPC-157 | Ulcerative colitis (use FDA evaluated) | Sep 2023 (day not given) | 22 Apr 2026, nominations withdrawn by the nominators | Not in Category 1, 2 or 3; not on the 503A bulks list | 23 Jul 2026: yes 8, no 6, abstain 1; recommended (secondary source: law-firm summary; FDA has published no counts). FDA staff proposed NOT listing either form. | Yes. Appendix B: acetate; subcutaneous, intramuscular, oral and topical dosage forms | none listed on FDA's safety page | No proposed rule found. HHS policy comments closed 13 Nov 2026; no final version or date published. | B E F G H A |
| KPV | Wound healing and inflammatory conditions | Sep 2023 (day not given) | 22 Apr 2026, nominations withdrawn by the nominators | Not in Category 1, 2 or 3 | 23 Jul 2026: yes 8, no 6, abstain 1; recommended (secondary source: law-firm summary; FDA has published no counts). FDA staff proposed NOT listing either form. | Yes. Appendix B: acetate; topical and oral dosage forms | none listed on FDA's safety page | No proposed rule found. HHS policy comments closed 13 Nov 2026; no final version or date published. | B E F G H A |
| TB-500 (thymosin beta-4 fragment LKKTETQ) | Wound healing | 29 Sep 2023 | 22 Apr 2026, nominations withdrawn by the nominators | Not in Category 1, 2 or 3 | 23 Jul 2026: yes 8, no 6, abstain 1; recommended (secondary source: law-firm summary; FDA has published no counts). FDA staff proposed NOT listing either form. | Yes. Appendix B: acetate; subcutaneous or intramuscular injectable dosage forms | none listed on FDA's safety page | No proposed rule found. HHS policy comments closed 13 Nov 2026; no final version or date published. | B E F G H A |
| MOTS-c | Obesity and osteoporosis | 29 Sep 2023 | 22 Apr 2026, nominations withdrawn by the nominators | Not in Category 1, 2 or 3 | 23 Jul 2026: yes 7, no 5, abstain 2; recommended (secondary source: law-firm summary; FDA has published no counts). FDA staff proposed NOT listing either form. | Yes. Appendix B: acetate; subcutaneous or intramuscular injectable dosage forms | none listed on FDA's safety page | No proposed rule found. HHS policy comments closed 13 Nov 2026; no final version or date published. | B E F G H A |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia and narcolepsy | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | 24 Jul 2026: yes 6, no 7, abstain 1; not recommended (secondary source: law-firm summary; FDA has published no counts). FDA staff proposed NOT listing either form. | No (not in Appendix A) | none listed on FDA's safety page | None published. FDA has announced no step after the negative vote. | B E F G A |
| Epitalon | Insomnia | 29 Sep 2023 | 22 Apr 2026, nominations withdrawn by the nominators | Not in Category 1, 2 or 3 | 24 Jul 2026: yes 7, no 4, abstain 1; recommended (secondary source: law-firm summary; FDA has published no counts). FDA staff proposed NOT listing either form. | Yes. Appendix B: acetate; subcutaneous or intramuscular injectable dosage forms dispensed in intermittent courses | none listed on FDA's safety page | No proposed rule found. HHS policy comments closed 13 Nov 2026; no final version or date published. | B E F G H A |
| Semax | Cerebral ischemia, migraine and trigeminal neuralgia | 29 Sep 2023 | 22 Apr 2026, nominations withdrawn by the nominators | Not in Category 1, 2 or 3 | 24 Jul 2026: yes 8, no 5, abstain 1; recommended (secondary source: law-firm summary; FDA has published no counts). FDA staff proposed NOT listing either form. | Yes. Appendix B: free base; intranasal use | none listed on FDA's safety page | No proposed rule found. HHS policy comments closed 13 Nov 2026; no final version or date published. | B E F G H A |
| Ipamorelin (free base and acetate) | Growth hormone deficiency and postoperative ileus | 503A: date not published (503B: 29 Sep 2023) | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | 29 Oct 2024: yes 0, no 12, abstain 1 for each form; not recommended (FDA final summary minutes). FDA staff proposed NOT listing. | No | Category 2 since 29 Sep 2023 | None published. | B C I A |
| Ibutamoren mesylate | Growth hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity, Alzheimer's disease | 29 Sep 2023 (503B: 29 Dec 2022) | Not removed | Category 2 | 29 Oct 2024: yes 1, no 13, abstain 0; not recommended (FDA final summary minutes). FDA staff proposed NOT listing. | No | Category 2 since 29 Dec 2022 | None published. | A B C I |
| Kisspeptin-10 | Secondary hypogonadism in men | 29 Sep 2023 | Not removed | Category 2 | 29 Oct 2024: yes 0, no 11, abstain 0; not recommended (FDA final summary minutes). FDA staff proposed NOT listing. | No | none listed on FDA's safety page | None published. | A B C I |
| CJC-1295 (five forms, with and without DAC) | Growth hormone deficiency | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | 4 Dec 2024: committee did not agree to a single vote (yes 12, no 1). Separate votes, yes/no/abstain: free base 0/13/0; acetate 1/12/0; DAC free base 0/13/0; DAC acetate 0/13/0; DAC trifluoroacetate 0/13/0. Not recommended (FDA final summary minutes). FDA staff proposed NOT listing. | No | none listed on FDA's safety page | None published. | B D J A |
| AOD-9604 (free base and acetate) | Obesity | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | 4 Dec 2024: single vote agreed (yes 12, no 0); placement vote yes 0, no 12, abstain 0; not recommended (FDA final summary minutes). FDA staff proposed NOT listing. | No | none listed on FDA's safety page | None published. | B D J A |
| Thymosin alpha-1 (free base and acetate) | 13 uses FDA evaluated, among them hepatitis B and C, HIV, sepsis, COPD and ME/CFS | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | 4 Dec 2024: single vote not used (yes 20, no 1). Free base yes 4, no 17, abstain 0; acetate yes 4, no 17, abstain 0; not recommended (FDA final summary minutes). FDA staff proposed NOT listing. | No | none listed on FDA's safety page | None published. | B D J A |
| GHK-Cu | Not published on the pages read | Injectable routes were in Category 2: date not published | All routes left Category 1 on 22 Apr 2026 (nominations withdrawn); the non-injectable route was added back (nominator clarified 5 May 2026). Injectable nomination withdrawn. | Category 1, except injectable routes | None yet. FDA says it intends to consult the PCAC before the end of Feb 2027. | No | none listed on FDA's safety page | FDA intends to consult the PCAC before the end of February 2027; meeting date not set. | A B |
| GHRP-2 | Not published on the pages read | 503A: no Category 2 entry shown (503B: 29 Sep 2023, injectable and nasal routes) | Not applicable | Category 3 | None | No | Category 2 since 29 Sep 2023 (injectable and nasal) | None published. | A B |
| GHRP-6 | Not published on the pages read | 503A: no Category 2 entry shown (503B: 29 Sep 2023) | Not applicable | Category 3 | None | No | Category 2 since 29 Sep 2023 | None published. | A B |
| Mechano growth factor (MGF) | Not published on the pages read | Not applicable | Not applicable | Category 3 | None | No | none listed on FDA's safety page | None published. | A |
| PEG-MGF (mechano growth factor pegylated) | Not published on the pages read | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | None | No | none listed on FDA's safety page | None published. | A B |
| Cibinetide (ARA-290) | Not published on the pages read | Not applicable | Not applicable | Category 3 | None | No | none listed on FDA's safety page | None published. | A |
| Thymulin acetate | Not published on the pages read | Not applicable | Not applicable | Category 3 | None | No | none listed on FDA's safety page | None published. | A |
| Secretin, human 99% | Not published on the pages read | Not applicable | Not applicable | Category 3 | None | No | none listed on FDA's safety page | None published. | A |
| Vasoactive intestinal peptide (VIP) | "Chronic inflammatory response syndrome" (CIRS) | Not applicable | Not applicable | Category 1 | 3 Nov 2016: PCAC voted not to include it; FDA had proposed not listing it (as stated in FDA's 2019 proposed rule) | No | none listed on FDA's safety page | FDA proposed on 5 Sep 2019 (84 FR 46688) not to place VIP on the list; we found no final rule. | A K |
| Cathelicidin LL-37 | Not published on the pages read | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | None | No | none listed on FDA's safety page | None published. | A B |
| Dihexa acetate | Not published on the pages read | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | None | No | none listed on FDA's safety page | None published. | A B |
| Melanotan II | Not published on the pages read | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | None | No | none listed on FDA's safety page | None published. | A B |
| Selank acetate (TP-7) | Not published on the pages read | Date not published | Listed by FDA as nominated but withdrawn; date not published | Not in Category 1, 2 or 3 | None | No | none listed on FDA's safety page | None published. | A B |
The 503B column reflects FDA's Category 2 safety page only; we did not read FDA's 503B categories list. "None listed on FDA's safety page" in the 503B column means the peptide does not appear on FDA's Category 2 safety page with a 503B entry. We did not read FDA's separate 503B category list, so it is not proof of no 503B entry. FDA's "nominated but withdrawn" table does not say whether a withdrawn nomination was for 503A or 503B, and gives no per-substance dates; the 22 April 2026 removal date for the six HHS peptides comes from HHS's Appendix B. July 2026 tallies are not from FDA; the 2024 tallies are from FDA's final summary minutes. Ibutamoren is a growth hormone secretagogue included because it went to the same 2024 meeting.
Sources and read dates
- A FDA 503A categories list, updated 14 May 2026, read 17 November 2026
- B FDA Category 2 safety page (content current 22 Apr 2026), read 17 November 2026
- C FDA final summary minutes, PCAC 29 Oct 2024, read 17 November 2026
- D FDA final summary minutes, PCAC 4 Dec 2024, read 17 November 2026
- E FDA meeting page, PCAC 23 to 24 Jul 2026, read 17 November 2026
- F FDA briefing document introduction, PCAC Jul 2026 (staff proposals), read 17 November 2026
- G HHS enforcement discretion policy with Appendices A and B (hhs.gov), read 17 November 2026
- H Federal Register notice, 91 FR 68526, FR Doc 2026-22192, read 17 November 2026
- I FDA meeting page, PCAC 29 Oct 2024, read 17 November 2026
- J FDA meeting page, PCAC 4 Dec 2024, read 17 November 2026
- K FDA proposed rule, 84 FR 46688, FR Doc 2019-18951, read 17 November 2026
HHS did not return its policy file to our automated request on 17 November 2026, so we read an archived copy of the same hhs.gov file and checked its dates and routes against the Federal Register notice and against our own earlier reading of the live file.
What is not known
- No proposed rule. We found no FDA proposed rule adding any peptide to the 503A bulks list. On 17 November 2026 we searched the Federal Register for FDA proposed and final rules published since 1 January 2019 containing "503A" or "bulk drug substances". The only rules on the 503A bulks list it returns are the February 2019 final rule that created the list (84 FR 4696, no peptides placed on it) and a September 2019 proposal (84 FR 46688) that would place five substances on it and proposed not to list VIP; we found no final rule on that proposal. The HHS notice says only that FDA rulemaking "may propose adding some or all of these peptides".
- The July 2026 vote counts are not official. FDA's meeting page lists the agenda and briefing documents but no minutes or tallies as of our reading. The figures come from a law-firm summary of the meeting. See every tally and how we cross-checked them.
- The second PCAC meeting is not dated. FDA says it intends to consult the committee on GHK-Cu before the end of February 2027. No date is set.
- The HHS policy has no final version yet. The comment period closed on 13 November 2026. When we read the docket on 17 November 2026 (12:25 UTC) it showed 115 published of 289 received comments (who filed them; docket on regulations.gov). The notice gives no date for a final version, and says HHS may revisit the policy.
- Several dates are missing. FDA does not publish when most withdrawn substances entered or left Category 2.
Enforcement and warning-letter history sits in the enforcement tracker. For the consumer question, "are peptides legal", see the US legal status guide.
How to cite this page
Free to use under CC BY 4.0 with credit and a link. Data download: peptide-503a-status-2026.csv (the same columns plus source URLs and read date).
Suggested citation: Peptide Bureau editorial desk. "Where every peptide stands on the FDA 503A bulks list." Peptide Bureau, 17 November 2026. https://peptidebureau.com/peptide-503a-bulks-list-status.html.
Corrections
Spotted an error or a newer FDA or HHS document? Email [email protected]. Corrections are dated on this page. None so far.
Not legal advice. This page records what public documents say about compounding rules. It does not say what any pharmacy, physician or buyer may lawfully do. Research peptides sold for laboratory use are a different matter and are not covered by any row above.